0001437749-21-022057.txt : 20210913 0001437749-21-022057.hdr.sgml : 20210913 20210913192940 ACCESSION NUMBER: 0001437749-21-022057 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210910 FILED AS OF DATE: 20210913 DATE AS OF CHANGE: 20210913 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Echerd Margaret CENTRAL INDEX KEY: 0001530193 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35285 FILM NUMBER: 211250873 MAIL ADDRESS: STREET 1: 3585 MONROE STREET CITY: SANTA CLARA STATE: CA ZIP: 95051 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxart, Inc. CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 170 HARBOR WAY, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 550-3500 MAIL ADDRESS: STREET 1: 170 HARBOR WAY, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: Aviragen Therapeutics, Inc. DATE OF NAME CHANGE: 20160413 FORMER COMPANY: FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20121113 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20100719 4 1 rdgdoc.xml FORM 4 X0306 4 2021-09-10 0000072444 Vaxart, Inc. VXRT 0001530193 Echerd Margaret C/O VAXART, INC. 170 HARBOR WAY, SUITE 300 SOUTH SAN FRANCISCO CA 94080 1 SVP, Principal Accntng Officer Common Stock 2021-09-10 4 M 0 334 5.17 A 334 D Common Stock 2021-09-10 4 M 0 1467 0.77 A 1801 D Common Stock 2021-09-10 4 S 0 1801 9.10 D 0 D Stock Option (Right to Buy) 5.17 2021-09-10 4 M 0 334 0 D 2028-05-24 Common Stock 334 2333 D Stock Option (Right to Buy) 0.77 2021-09-10 4 M 0 1467 0 D 2029-06-11 Common Stock 1467 29352 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2021. The stock option vests over a four-year period, with 25% of the shares subject to the stock option vesting on the first anniversary of the vesting commencement date of April 9, 2018, and the remaining shares in 36 equal monthly installments thereafter. The stock option vests over a four-year period, with 25% of the shares subject to the stock option vesting on the first anniversary of the vesting commencement date of May 10, 2019, and the remaining shares in 36 equal monthly installments thereafter. /s/ Margaret Echerd 2021-09-13